271 related articles for article (PubMed ID: 27479820)
41. Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
[TBL] [Abstract][Full Text] [Related]
42. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
[TBL] [Abstract][Full Text] [Related]
43. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
Das-Gupta E; Thomson KJ; Bloor AJC; Clark AD; Mackinnon S; Kayani I; Clifton-Hadley L; Patrick P; El-Mehidi N; Lawrie A; Kirkwood AA; Russell NH; Linch DC; Peggs KS
Blood Adv; 2019 Dec; 3(24):4264-4270. PubMed ID: 31869413
[TBL] [Abstract][Full Text] [Related]
44. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
[TBL] [Abstract][Full Text] [Related]
45. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases.
Gualco G; Natkunam Y; Bacchi CE
Mod Pathol; 2012 May; 25(5):661-74. PubMed ID: 22222636
[TBL] [Abstract][Full Text] [Related]
46. Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing.
Cho J; Yoon SE; Kim SJ; Ko YH; Kim WS
BMC Cancer; 2021 Aug; 21(1):972. PubMed ID: 34461835
[TBL] [Abstract][Full Text] [Related]
47. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941
[TBL] [Abstract][Full Text] [Related]
48. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
49. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
50. Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma.
Drees EEE; Roemer MGM; Groenewegen NJ; Perez-Boza J; van Eijndhoven MAJ; Prins LI; Verkuijlen SAWM; Tran XM; Driessen J; Zwezerijnen GJC; Stathi P; Mol K; Karregat JJJP; Kalantidou A; Vallés-Martí A; Molenaar TJ; Aparicio-Puerta E; van Dijk E; Ylstra B; Groothuis-Oudshoorn CGM; Hackenberg M; de Jong D; Zijlstra JM; Pegtel DM
J Extracell Vesicles; 2021 Jul; 10(9):e12121. PubMed ID: 34295456
[TBL] [Abstract][Full Text] [Related]
51. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
Trkulja KL; Manji F; Kuruvilla J; Laister RC
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
[TBL] [Abstract][Full Text] [Related]
52. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
[TBL] [Abstract][Full Text] [Related]
53. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
[TBL] [Abstract][Full Text] [Related]
54. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
56. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
[TBL] [Abstract][Full Text] [Related]
57. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.
Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Pozzi S; Ferrari A; Baldini L; Gobbi P; Aviv A; Pugliese G; Federico M; Polliack A; Sacchi S
Hematol Oncol; 2017 Dec; 35(4):561-566. PubMed ID: 27791277
[TBL] [Abstract][Full Text] [Related]
58. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
[TBL] [Abstract][Full Text] [Related]
59. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Gunawardana J; Chan FC; Telenius A; Woolcock B; Kridel R; Tan KL; Ben-Neriah S; Mottok A; Lim RS; Boyle M; Rogic S; Rimsza LM; Guiter C; Leroy K; Gaulard P; Haioun C; Marra MA; Savage KJ; Connors JM; Shah SP; Gascoyne RD; Steidl C
Nat Genet; 2014 Apr; 46(4):329-35. PubMed ID: 24531327
[TBL] [Abstract][Full Text] [Related]
60. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R
J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
